Cathie Wood’s ARK ETF has increased its holdings in CRISPR stock while reducing its position in Moderna. According to Investing.com, this move reflects ARK’s confidence in the potential of CRISPR technology. Wood’s ETF has been actively managing its portfolio to capitalize on emerging trends in the biotech sector. This decision to bolster CRISPR stock and trim Moderna indicates ARK’s strategic approach to investing in innovative companies.
Subscribe
Login
0 Comments